Technology ID
TAB-2649
Novel Live-Attenuated Rabies Vaccine
E-Numbers
E-326-2013-0
Lead Inventor
Rupprecht, Charles (CDC)
Co-Inventors
Wu, Xianfu (CDC)
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Status
- Pre-clinical
- In vitro data available
- In vivo data available (animal)
Lead IC
CDC
ICs
CDC
The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge.
Commercial Applications
- Rabies vaccine design and development
- Immunogenic compositions for both prevention and treatment of rabies virus
- Rabies virus research
Competitive Advantages
- Live attenuated vaccine shows greater efficacy than older inactivated vaccine
- 100% animal survival conferred by a single inoculation before lethal challenge
Licensing Contact: